Get the Stockscreener App
8.9001
3.26%
0.000100
Surrozen Inc stock is traded at $8.9001, with a volume of 6,507.
It is up +3.26% in the last 24 hours and down -2.03% over the past month.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
See More
Previous Close:
$8.90
Open:
$9.66
24h Volume:
6,507
Relative Volume:
0.32
Market Cap:
$32.50M
Revenue:
-
Net Income/Loss:
$-53.45M
P/E Ratio:
-7.4168
EPS:
-1.2
Net Cash Flow:
$-31.81M
1W Performance:
-3.06%
1M Performance:
-2.03%
6M Performance:
-5.36%
1Y Performance:
+2,186%
1-Day Range:
$9.10
$9.75
1-Week Range:
$8.10
$10.76
52-Week Range:
$0.40
$16.19
Surrozen Inc Stock (SRZN) Company Profile
Name
Surrozen Inc
Sector
Industry
Phone
650-475-2820
Address
171 OYSTER POINT BLVD, SOUTH SAN FRANCISCO
Compare SRZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| SRZN | 9.21 | 32.50M | 0 | -53.45M | -31.81M | -1.20 |
| VRTX | 448.26 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.57 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.72 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.24 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Surrozen Inc Stock (SRZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Sep-15-21 | Initiated | Guggenheim | Buy |
| Sep-07-21 | Initiated | Stifel | Buy |
Surrozen Inc Stock (SRZN) Latest News
Trading (SRZN) With Integrated Risk Controls - Stock Traders Daily
Surrozen (NASDAQ:SRZN) Stock Price Down 7% – Here’s Why - Defense World
Stonepine Capital Management, LLC Increases Stake in Surrozen Inc - GuruFocus.com
Goldman Sachs Group Inc's Strategic Investment in Surrozen Inc - GuruFocus.com
Surrozen to Present at Upcoming Healthcare Investor Conferences - The Manila Times
Surrozen (SRZN) to Present at Guggenheim and Stifel Healthcare Conferences | SRZN Stock News - StockTitan
Surrozen Provides Third Quarter 2024 Financial Results and Business Update - ForexTV.com
(SRZN) Trading Signals - Stock Traders Daily
Surrozen partners with TCGFB for lung disease therapy By Investing.com - Investing.com Canada
Surrozen partners with TCGFB for lung disease therapy - Investing.com India
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis - The Manila Times
StemPoint Capital LP Increases Stake in Surrozen Inc - GuruFocus.com
Trend Tracker for (SRZN) - Stock Traders Daily
Surrozen (NASDAQ:SRZN) Trading Up 4.3% – Here’s What Happened - Defense World
How To Trade (SRZN) - Stock Traders Daily
This Week's Bay Area Deal Sheet (October 10, 2024) - Bisnow
Surrozen extends South San Francisco headquarters lease By Investing.com - Investing.com Australia
Surrozen extends South San Francisco headquarters lease - Investing.com India
187,206 Shares in Surrozen, Inc. (NASDAQ:SRZN) Purchased by Nantahala Capital Management LLC - Defense World
Stonepine Capital Management LLC Invests $724,000 in Surrozen, Inc. (NASDAQ:SRZN) - Defense World
CVI Holdings LLC Makes New Investment in Surrozen, Inc. (NASDAQ:SRZN) - Defense World
Column Group LLC Makes New Investment in Surrozen, Inc. (NASDAQ:SRZNW) - Defense World
Boehringer Ingelheim to advance SZN-413 for retinal diseases - BioWorld Online
Patrick Brennan joins Selective Insurance as CFO - Reinsurance News
Surrozen and Boehringer Ingelheim advance SZN-413 development By Investing.com - Investing.com South Africa
Streamline Health CEO buys $1,008 in company stock By Investing.com - Investing.com UK
Selective Insurance appoints Patrick Brennan as chief financial officer - ROI-NJ.com
Surrozen and Boehringer Ingelheim advance SZN-413 development - Investing.com India
Surrozen earns $10M milestone payment in Retinal Diseases collaboration - TipRanks
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration - GlobeNewswire
SThree Q3 net fees slip 8% amid challenging conditions - Staffing Industry Analysts
FINANCIALS: SThree reports 8% drop due to challenging conditions - Recruiter
Sagefield Capital LP Invests $2.35 Million in Surmodics, Inc. (NASDAQ:SRDX) - MarketBeat
Selective taps Progressive’s Brennan to fill CFO role on permanent basis - Re-Insurance.com
Recruiter SThree holds guidance despite ‘challenging’ market conditions - City A.M.
Selective lands Progressive’s Brennan as CFO, one year after Wilcox exit - Insurance Insider US
Selective Insurance Appoints Patrick S. Brennan as Chief Financial Officer - StockTitan
Plenham Limited statement: Jason Moseley - Bodyshop Magazine
Surrozen (NASDAQ:SRZN) Shares Up 2.4% - Defense World
(SRZN) Investment Analysis - Stock Traders Daily
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.60% - MSN
How to Take Advantage of moves in (SRZN) - Stock Traders Daily
Head to Head Comparison: 4D Molecular Therapeutics (NASDAQ:FDMT) vs. Surrozen (NASDAQ:SRZN) - Defense World
Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation - Simply Wall St
SRZN Stock Earnings: Surrozen Misses EPS for Q2 2024 - InvestorPlace
Surrozen Provides Second Quarter 2024 Financial Results and Business Update - GlobeNewswire
Surrozen (NASDAQ:SRZN) and AIM ImmunoTech (NYSE:AIM) Head-To-Head Comparison - Defense World
Surrozen (NASDAQ:SRZN) Stock Price Up 1.3% - Defense World
(SRZN) Trading Report - Stock Traders Daily
Surrozen (NASDAQ:SRZN) Stock Price Down 10.4% - Defense World
Surrozen announces director resignation - Investing.com India
Surrozen Inc Stock (SRZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Surrozen Inc Stock (SRZN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| COLUMN GROUP III GP, LP | 10% Owner |
Apr 04 '24 |
Buy |
15.50 |
193,548 |
2,999,994 |
332,885 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):